A U.S. based vaccine development company is set to begin the second phase of human testing for its COVID-19 vaccine in South Africa, which is in the midst of a surge in coronavirus cases.
Novavax said in a statement that the clinical trials will include 2,665 healthy adults in South Africa.
The trials will also compare the vaccine’s effect on 240 medically stable adults with HIV whose immune responses may differ from individuals without HIV.
Preliminary findings from the first trial showed people receiving the two doses generated neutralizing…
